canonical capping pathway with four sequential events that involve several viral nsp's: (i) first, the 5=-3=helicase/nucleoside triphosphatase (NTPase) nsp13 hydrolyzes the ␥-phosphate from nascent 5=-triphosphate RNA (23) ; (ii) then, a GMP molecule is transferred to 5=-diphosphate RNA by an as-yet-unknown GTase, thus forming a primitive cap structure (GpppN); (iii) then, the guanosine is methylated, at the N7 position, by nsp14 in the presence of the methyl donor S-adenosyl-L-methionine (SAM) to produce the cap-0 structure ( 7m GpppN) and S-adenosyl-homocysteine (SAH) as by-product (24) ; and (iv) finally, the nsp10/nsp16 complex methylates the 2=-OH group (ribose) of the first transcribed nucleotide of the viral RNA, leading to the conversion of the cap-0 into a cap-1 structure ( 7m GpppN 2=om ) (25, 26) . Thus, in CoVs, RNA cap methylation might involve at least three proteins (nsp10, nsp14, and nsp16), and it is known that both nsp14 and nsp16 can interact with nsp10 (27) .
CoV 2=-O-MTase activity is mediated by nsp16 that contains both a conserved K-D-K-E catalytic tetrad, which is characteristic of SAM-dependent 2=-O-MTases, and a conserved SAM-binding site (28) . CoV 2=-O-MTase activity was first demonstrated using in vitro biochemical assays with purified feline CoV (FCoV) nsp16 (29) . However, recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) nsp16 was inactive using similar experimental conditions. It was then demonstrated that SARS-CoV nsp16 needs to interact with nsp10 to become catalytically active (25) . The nsp10/ nsp16 complex MTase activity was demonstrated using synthetic capped N7-methylated RNA and longer RNAs that mimic the 5= end of the SARS-CoV genome (25) . In contrast, RNA with an unmethylated cap structure (Gppp-RNA) was not recognized by the nsp10/nsp16 complex, and no enzymatic activity was detected. Several mutagenesis studies of SARS-CoV nsp10 and nsp16 confirmed the key role of the K-D-K-E catalytic tetrad for the 2=-O-MTase activity (30) and demonstrated that the interaction between nsp10 and nsp16 is absolutely required for this activity (30, 31) . The molecular basis governing nsp16 stimulation by nsp10 was partially elucidated by the crystal structure determination of the SARS-CoV nsp10/nsp16 complex (26, 30) . The nsp16 adopts the catechol O-MTase fold containing alternating ␤ strands (␤1 to ␤7) and ␣ helices (␣Z and ␣A to ␣E) that form a seven-stranded ␤ sheet with three ␣ helices on each side (30, 32) . In addition, nsp10 binds to nsp16 through a 930-Å 2 activation area on nsp10 and stabilizes nsp16 (25, 26, 30, 33) . Moreover, structural and biochemical analyses also suggest that nsp10 binding extends and narrows the RNA binding groove to accommodate the RNA substrate and enhances nsp16 RNA-and SAM-binding properties.
Although cap 2=-O-MTases are present in different virus families (15) , the exact role of this RNA-cap modification was only recently unraveled through reverse genetic studies performed, among others, on CoV (16) (17) (18) (19) . Single point mutations in the conserved K-D-K-E tetrad of nsp16 have revealed a barely attenuated phenotype in infected cells (16, 34) . In contrast, infection of small animal models by viruses expressing nsp16 with active-site substitution showed a robust reduction of viral titers and less severe infection symptoms (weight loss, lung histology, and breathing function) concomitantly with a strong antiviral response, possibly linked to stimulation of the innate immunity. Indeed, it was shown that incompletely capped RNA can be detected by RIG-I or Mda5 (16, 18, 19) , leading to the initiation of a signaling cascade that stimulates the secretion of type I interferon (IFN) and induces an antiviral response in neighboring cells. Altogether, these observations indicate that the inhibition of the viral 2=-O-MTase activity might stimulate the detection of viral RNAs by RIG-I or Mda5 and restore the host antiviral response mediated by ISGs such as IFIT proteins (35) .
In this study, we assessed the biochemical activity of the MERS-CoV nsp10/nsp16 complex MTase. We show that MERS-CoV nsp16 possesses 2=-O-MTase activity. As previously shown, nsp16 is stimulated by nsp10 and leads to 2=-O-methylation of cap-0 RNA (33) . Biochemical assays were used to decipher the fine-tuning of the reaction turnover. Mutagenesis combined with RNA binding assays identified the residues essential for cap-0 recognition and those forming the RNA binding groove. Finally, using our radioactive enzymatic assay, we screened a small subset of MTase inhibitors blocking nsp10/nsp16 MTase activity, and the compounds blocking RNA recognition were identified using a fluorescence polarization assay.
RESULTS
MERS-CoV nsp16 assembles with nsp10 to constitute an active SAM-dependent cap-0 2=-O-methyltransferase. The CoV nsp16 2=-O-MTase contains both a conserved K-D-K-E catalytic tetrad, which is characteristic of SAM-dependent 2=-O-MTase, and a conserved SAM-binding site (28) . Although purified feline CoV (FCoV) nsp16 shows a weak 2=-O-MTase activity in the absence of nsp10, SARS-CoV nsp16 2=-O-MTase activity is strictly dependent on its interaction with nsp10 (29, 33) . MERS-CoV nsp16 shows ϳ65 and ϳ53% amino acid residue similarity with SARS-CoV and FCoV nsp16, respectively, and requires nsp10 for nsp16 2=-O-MTase activity (33) . To assess the mechanism of fine-tuning of MERS-CoV nsp16 2=-O-MTase activity by nsp10, recombinant nsp10 and nsp16 with an N-terminal His 6 -tag were produced and purified, and SDS-PAGE analysis showed that nsp10 and nsp16 migrate at the expected molecular masses (Fig. 1A, 16 and 37 kDa, respectively), and their identity was confirmed by mass spectrometry after trypsin digestion (not shown). The nsp10/nsp16 complex was obtained by colysis of an equal volume of His 6 -nsp10 and His 6 -nsp16 expressing bacteria and purification by immobilized metal affinity chromatography (IMAC) and size exclusion chromatography. The chromatogram (Fig. 1B) indicated that the nsp10/nsp16 complex was detected as one major peak eluting at a volume corresponding to an nsp10/nsp16 heterodimer (ϳ50 kDa).
Then, in vitro MTase assays were performed using RNA oligonucleotides with sequences corresponding to the 5= end of the MERS-CoV genome with various 5=-end modifications (pppGAUUUAA, GpppGAUUUAA, 7m GpppGAUUUAA, GpppG 2=om AUUUAA, and 7m GpppG 2=om AUUUAA) in the presence of nsp10 or nsp16 alone or as a complex and of 3 H-SAM as methyl donor. Quantification of the amount of [ 3 H]CH 3 transferred to RNA over time using a DEAE filter-binding assay indicated the absence of MTase activity when nsp10 or nsp16 alone was used (Fig. 1C) . Conversely, RNA carrying a cap-0 structure ( 7m GpppGAUUUAA) was methylated in a time-dependent manner when incubated with both nsp16 and nsp10 or with the purified nsp10/nsp16 complex. Since MTase activity was detected only using 7m GpppGAUUUAA, but not GpppG 2=om AUUUAA or 7m GpppG 2=om AUUUAA, we hypothesized that the MERS-CoV MTase converts cap-0 into cap-1 RNA. The addition of a single methyl group on 7m GpppGAUUUAA was confirmed by comparing the molecular mass of 7m GpppGAUUUAA before and after incubation with nsp10/nsp16 and SAM. We detected a mass increase of about ϳ14.2 Da by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry analysis indicating that one methylation event has occurred. We conclude that MERS-CoV nsp16 carries the cap 2=-O-MTase activity and is stimulated by nsp10. The nsp10 stimulation effect on nsp16 was confirmed by assessing nsp16 2=-O-MTase activity in the presence of increasing concentrations of nsp10. An apparent dissociation constant for the nsp10/nsp16 complex could be derived from the stimulation curves Fig. 2A) . Moreover, the nsp10/nsp16 MTase activity required the addition of divalent ions (Mg ϩϩ or Mn ϩϩ ) and was inhibited by EDTA (Fig. 2B ). The optimum of activity peaked between pH 8 and 8.5 (Fig. 2C) . The optimal concentration of methyl-donor (SAM) (K d ϭ 4.3 Ϯ 0.6 M) was also determined by measuring the MTase activity of the complex in the presence of increasing SAM concentrations (Fig.  2D) . Finally, MTase assays performed using the optimal conditions deduced from these biochemical assays and cap-0 RNAs with sequences corresponding to the 5= ends of various viruses showed that the nsp10/nsp16 complex methylated cap-0 RNAs that started with either an A or a G (Fig. 2E) . Taken together, these results suggest that MERS-CoV nsp16 acts as an nsp10-dependent 2=-O-MTase that converts cap-0 into cap-1 RNA structures with no obvious specific recognition mechanism of the MERS-CoV sequence. Moreover, the absence of 2=-O-MTase activity using GpppRNA suggests that nsp16 can discriminate the cap-0 structure from an unmethylated cap structure.
The MERS-CoV nsp10/nsp16 complex recognizes specifically a cap-0 structure, and downstream RNA nucleotides promote loading of cap-0 substrate and their 2=O methylation. RNA binding assays were then developed to determine why the nsp10/nsp16 complex was active only on cap-0 RNA. For this purpose, the 3= ends of various 5=-end-modified RNAs were labeled with pCp-cy5 (where cy5 represents cyanin 5), and then their binding to freshly purified MERS-CoV nsp10/nsp16 complex was measured in fluorescence polarization assays. The nsp10/nsp16 complex recognized only cap-0 RNA ( 7m GpppRNA) with a K d of ϳ0.35 M (Fig. 3A) . No significant binding was detected using the other RNAs (pppRNA or GpppRNA, GpppG 2=om RNA, and The nsp10/nsp16 complex was purified by gel filtration using a S200-16/60 column. The elution chromatogram (optical density, 280 nm) shows one main peak that eluted at 90 ml and corresponded to the nsp10/nsp16 complex. (C) The methyltransferase activities (MTase) of nsp16 (1.2 M) and nsp10 (2 M) alone or together and of the nsp10/nsp16 complex (1 M) were determined by monitoring the transfer of 3 H-CH 3 from SAM to RNA oligonucleotides with sequences corresponding to the 5= end of the MERS-CoV genome with various cap modifications (pppGAUUUAA, GpppGAUUUAA, 7m GpppGAUUUAA, GpppG 2=om AUUUAA, and 7m GpppG 2=om AUUUAA). Assays were stopped after 5, 30, 60, and 180 min, and the radioactivity associated with the RNA was determined by a DEAE-filter binding assay. The bar graph presents the means and standard deviations of three independent experiments. 7m GpppG 2=om RNA). This observation is consistent with the MTase assay results (Fig. 1C) and indicates that the absence of nsp10/nsp16 2=-O-MTase activity using GpppRNA is due to the lack of recognition of such capped RNA. It also suggests that the nsp10/ nsp16 complex has an RNA binding site that recognizes specifically cap-0 RNA. More- Table 1 . (E) Kinetics of MTase activity of the nsp10/nsp16 complex (0.25 M) on 7m GpppG-RNAs (0.7 M) of increasing length was measured by filter binding assay after 2, 4, 8, 16, 32, and 64 min of incubation at 30°C in the presence of 3 H-SAM. The curve presents the means and standard errors of the means for three independent experiments. All the fluorescent polarization experiments were performed twice independently, and the K d values of each condition were calculated using GraphPad Prism (n ϭ 2, mean Ϯ the SEM) using one site-specific binding equation with the Hill slope.
over, the ability of this binding site to recognize cap-0 RNA is strongly regulated by the 2=-O-methylation status of the substrate RNA. Indeed, 7m GpppG 2=om RNA, which corresponds to the nsp16 2=-O-MTase reaction product, did not bind to the nsp10/nsp16 complex (Fig. 3A) . This indicates that cap-1 RNA generated by the nsp10/nsp16 2=-O-MTase activity is actively released, promoting the reaction turnover.
As nsp16 2=-O-MTase activity strictly depends on its interaction with nsp10 ( Fig. 1C  and 2A ), we then sought to determine whether nsp10 regulates nsp16 RNA-binding properties. Comparison of nsp10, nsp16, and nsp10/nsp16 complex binding to cap-0 RNA ( 7m GpppRNA) using a fluorescence polarization assay showed that nsp10 barely interacted with cap-0 RNA (Fig. 3B) . Conversely, both nsp16 and nsp10/nsp16 complex bound to cap-0 RNA with apparent K d values of ϳ1.4 and ϳ0.33 M, respectively. The polarization signal detected after nsp16 binding is higher than that obtained in the presence of the nsp10/nsp16 complex. This suggests that the RNA might bind to nsp16 dimers. Our result indicates that only nsp16 harbors the cap-0 binding site and that RNA binding is enhanced by nsp16 interaction with nsp10. Since nsp16 alone binds cap-0 RNA (Fig. 3B ) but is not methylated (Fig. 1C) , we suggest that nsp10 is an allosteric regulator of nsp16 2=-O-MTase activity. In addition, the methyl donor SAM and, to a lesser extent, the reaction by-product SAH increased the affinity for the RNA substrate (Fig. 3C) . Conversely, magnesium ions (Mg 2ϩ ), which stimulate nsp10/nsp16 MTase activity (Fig. 2B) , did not seem to affect RNA binding (Fig. 2F ) in these experimental conditions, indicating that magnesium ions are not required for RNA recognition.
The MTase assay showed that the nsp10/nsp16 complex is able to methylate cap-0 RNA of variable RNA sequences (Fig. 2E) , starting with either m GpppA or m GpppG. However, the MTase activity is weaker using short RNA substrates (Fig. 3E ). Therefore, we tested whether nucleotides downstream from the cap structure contributed to nsp10/nsp16 complex binding to RNA. To do this, fluorescence polarization assays were performed using 3=-end-labeled RNA sequences of increasing length that mimicked the 5= end of the MERS-CoV genome sequence. Quantification of their interaction with the nsp10/nsp16 complex ( Fig. 3D and Table 1) showed that the cap analogue 7m GpppGcy5, which was not methylated by nsp10/nsp16 (Fig. 3E ), barely interacted with the nsp10/nsp16 complex. In contrast, a significant interaction was observed using 7m GpppGAUU-cy5. The affinity then increased with the RNA length, and the optimal affinity was observed with 7m GpppGAUUUAAGUG-cy5 (Fig. 3D) . The MTase activity measured using a filter-binding assay followed the same trend (Fig. 3E) .
Identification of nsp16 residues playing a key role in RNA recognition and MTase activity. The crystal structure of the SARS-CoV nsp10/nsp16 complex with SAH has been reported at 2.0-Å resolution (30) . Since no structure with a cap analogue or substrate RNA is available yet, the nsp16 residues involved in RNA binding were tentatively inferred by modeling the RNA in the catalytic site (Fig. 4 : structural model based on the SARS-CoV and vaccinia MTase VP39 structures). Based on the structural model, alanine mutagenesis was performed, and the effects of nsp16 mutations on MTase activity (Fig. 5B ) and on RNA binding properties (Fig. 5A) were determined by filter binding assay and fluorescent polarization assay, respectively. Alanine substitution of the conserved residues in the catalytic tetrad (K-D-K-E) almost completely abolished the 2=-O-MTase activity, as expected. With the exception of D130A, these mutations also strongly reduced RNA binding, indicating that these catalytic residues also participated in RNA binding process. Mutation of the residues adjacent to the putative SAM binding site (H41, N43, D99, F149, and F150) drastically reduced MTase activity but had no significant effect on RNA binding. Mutation of K46, K170, E203, D133, R38, Y47, or Y181 concomitantly reduced MTase activity (80 to 100%) and RNA binding. These residues are localized in the putative RNA binding groove of nsp16 (Fig. 4) . In addition, mutation into alanine of Y30 and Y132, which are within two mobile ␣ helices (26-38 and 130-148) in close proximity to the cap in the nsp10/nsp16 model (Fig. 4) , and of H174, which is close to the 130-148 loop, also decreased nsp16 RNA binding properties and MTase activity. These observations confirm that the cap-0 RNA binding site involves these three aromatic residues. SAM and SAH levels regulate nsp10-nsp16 interaction. nsp16 2=-O-MTase activity requires interaction with nsp10. To determine how cosubstrate (SAM) availability might regulate the RNA-capping reaction pathway, the nsp16 interaction with nsp10 was analyzed using biolayer interferometry. nsp10 was biotinylated before immobilization on a streptavidin-coated biosensor. Binding of nsp16 was then monitored in the presence of various SAM/SAH concentrations, and the apparent affinity constants were determined (Fig. 6A and Table 2 ). The nsp16 interaction with biotinylated nsp10 increased in the presence of 100 M SAM or SAH. The interaction kinetics was characterized by the same association rate (same k on ) in the presence or in the absence of SAM or SAH. Conversely, the addition of SAM or SAH increased nsp10/nsp16 complex stability by decreasing the dissociation kinetics (k off ). This suggests that both SAM and SAH induce nsp10/nsp16 complex assembly. To further analyze how SAM or SAH regulated nsp10-nsp16 interaction, the dissociation of the nsp10/nsp16 complex, formed in the presence of 100 M SAM, was assessed using dissociation buffers containing various concentrations of SAM or SAH (Fig. 6B) . The dissociation rate of the nsp10/nsp16 complex depended on SAM or SAH concentration. In the presence of 100 M SAM, a concentration that mimics its intracellular level (36) , the nsp10/nsp16 complex stability was highest, as indicated by the slow nsp16 release. In contrast, after MTase reaction, which converts SAM into SAH, the latter is released from the enzyme at the lower intracellular concentration of SAH (ϳ20 M [37] ). In turn, the release of SAH will speed up the dissociation of the nsp10/nsp16 complex. Altogether, these data indicate that nsp10 and nsp16 form a dynamic complex, the association of which is promoted by SAM binding. The complex will dissociate when SAH, the reaction by-product, is released, thus favoring the reaction turnover. 
MERS-CoV nsp16
MTase activity inhibition. It was previously shown that 2=-Omethylation of viral RNA cap structures limited the infected host's antiviral response (38) , suggesting that molecules blocking nsp16 2=-O-MTase activity might favor viral clearance in infected animals (35) . In MTase inhibition assays, we tested 18 molecules known to block MTase activity (25, 39) . Four of these compounds (Fig. 7A ) inhibited nsp10/nsp16 2=-O-MTase activity (between 45 and 100%) at a concentration of 50 M. Among them, two SAM analogues (sinefungin and SAH, compounds 2 and 3 in Fig. 7A ) and showed the most potent inhibition. Cap-0 analogues ( 7m GpppG and 7m GpppA, compounds 18 and 16) also inhibited nsp16 2=-O-MTase activity (40 to 45%), whereas GpppG and GpppA (compounds 17 and 15) did not. This suggests that cap analogues block the binding of the RNA substrate in nsp16 RNA or cap binding site, in agreement with the weak interaction (K d Ͼ 20 M) of these compounds with the nsp10/nsp16 complex (Fig. 3D) .
To better define the 2=-O-MTase activity inhibition of sinefungin, SAH, 7m GpppG and 7m GpppA, the nsp10/nsp16 complex was preincubated with increasing concentrations of each inhibitor, and then the MTase reaction was started by the addition of 3 H-SAM and the RNA substrates. The dose-response curves (Fig. 7B) indicated that sinefungin and SAH inhibited nsp10/nsp16-mediated 2=-O-MTase activity, with 50% inhibitory concentrations (IC 50 s) in the micromolar range (7.4 and 7.0 M, respectively, Table 3 ). The IC 50 s of the cap analogues 7m GpppG and GpppG (45 and 274 M, respectively) (Table 3) suggest that 7m GpppG is a competitive inhibitor that blocks specifically the RNA cap-0 binding site. This was confirmed by measuring the effect of these compounds on nsp10/nsp16 RNA binding activity. 7m GpppG blocked RNA binding with an IC 50 of 45 M, which is in the same range of that of the inhibition of the MTase activity Table 2 . (B) Effects of SAM and SAH on the dissociation kinetics of nsp16 from immobilized nsp10. A 7.8 M concentration of nsp16 was bound to sensor-immobilized biotinylated nsp10 in the presence of 100 M SAM. The sensor was then moved to dissociation buffer alone or containing 5, 20, or 100 M SAM or SAH. nsp16 binding to immobilized nsp10 was normalized for each trace. (Fig. 7C) . Conversely, the SAM analogues (SAH and sinefungin), which are supposed to enter in the nsp16 SAM binding site, barely affected RNA binding properties, as expected. The K d values for the nsp10/nsp16 complex and 7m GpppRNA interactions in the presence or not of SAH or sinefungin were measured by fluorescence polarization (Fig. 7D) (12) . In this study, we characterized the MERS-CoV 2=-O-MTase activity of nsp16 and show that nsp10 is a cofactor required for nsp16 2=-O-MTase enzymatic activity, as previously reported for SARS and MERS-CoV (25, 33) . The substrate of the reaction is RNA with a cap-0 structure. This observation is consistent with RNA binding assays showing that N7-methylated cap RNA is recognized by the nsp10/nsp16 complex, whereas unmethylated RNA is not. Thus, MERS-CoV cap methylation follows an obligatory sequence in which 2=-O-methylation might occur after N7 methylation mediated by nsp14. Consequently, it is likely that RNA cap synthesis by MERS-CoV follows the canonical capping pathway observed in eukaryotic cells and in some viruses, such as SARS-CoV, dengue virus, and West Nile virus (20) .
Although the cap-0 structure gives RNA binding specificity, cap analogues barely bind to the nsp10/nsp16 complex at the micromolar concentration of 7m GpppG-cy5 used in our assay and are not a good substrate for the 2=-O-MTase. The presence of additional nucleotides downstream of the cap structure increases the substrate recognition and 2=-O-MTase activity. These nucleotides are thus required for substrate stabilization in the RNA binding groove. The optimal recognition is reached with 10 nt of capped RNA. This is consistent with the model proposed for the SARS-CoV nsp10/ nsp16 complex with 7m GpppA-RNA in which the first nucleotides are held by nsp16 and the following nucleotides might be positioned in a RNA binding groove stabilized by nsp10 (26, 30) . In addition, it is likely that the MERS-CoV 2=-O-MTase recognizes and methylates cap-0 RNA with no obvious sequence specificity. We also observed that the nsp10/nsp16 complex methylated similarly cap-0 RNA with A or G as the first nucleotide. This observation is in contrast to SARS-CoV 2=-O-MTase that preferentially binds and methylates RNA with A at N 1 position (( 7m GpppA-capped RNA, [26] ). Using synthetic RNAs that mimic the 5= end of the MERS-CoV genome, we did not observe any additional methylation (N2) or internal methylation, as indicated by the absence of enzymatic activity on cap-1 RNA or pppRNA sequences. The absence of internal methylation was also confirmed using longer (ϳ500 nt) pppRNA substrates (not shown). This observation contrasts with findings on other viral MTases (flavivirus NS5-MTase) that can perform internal methylation of adenosines (40) . Nevertheless, the absence of internal methylation with the nsp10/nsp16 complex is consistent with the fact that neither cap-1 RNAs nor pppRNAs interact with the nsp10/nsp16 complex.
To further understand the mechanism whereby nsp10 promotes the stimulation of nsp16 2=-O-MTase activity by nsp10, we determined whether nsp10 is required for substrate recognition process. Our findings indicate that nsp16 can recognize cap-0 RNA even in the absence of nsp10 as already reported for FCoV nsp16 (29) . Nevertheless, nsp10 increases nsp16 RNA binding properties of nsp16 (3-fold) and, in turn, the 2=-O-MTase activity can be detected only in the presence of both proteins under this condition. These observations suggest that nsp10 acts as an allosteric regulator of nsp16 2=-O-MTase activity rather than as an RNA binding module. A similar allosteric effect was reported for the vaccinia virus and human RNA N7-MTases. Indeed, in the vaccinia virus family, the D1 catalytic subunit alone is unstable and inactive, and its stability and MTase activity are enhanced by the presence of D12 through the increase in GTP, SAM, and GpppA binding affinity (41, 42) . Similarly, the human RNA N7 MTase (RNMT) is allosterically activated by RNMT activating miniprotein that stabilizes its structure and favors the recruitment of methyl donors (43) .
Since nsp10 is not the main player involved in RNA binding, we mapped the nsp16 residues involved in cap-0 RNA recognition. We could not determine the structure of nsp10/nsp16 with RNAs or cap analogues, although we performed many attempts (not shown). Therefore, we used alanine scanning mutagenesis to identify the residues involved in cap-0 RNA specific recognition and nsp16 MTase activity. Our results suggest that the cap-0 RNA structure is stacked between two flexible loops, 26-38 and 130-148, by the aromatic residues Y30 and Y132, respectively, and the H174 residue in close proximity. The alanine scanning results also indicate that the RNA chain of the substrate might be held by K46, K170, E203, D133, R38, Y47, and Y181 because both RNA binding and MTase activity decreased upon mutation of these residues. Interestingly, three residues belonging to the catalytic tetrad (K46, K170, and E203) might directly participate in RNA recognition. These results corroborate the model of MERSCoV nsp10/nsp16 (Fig. 4) in which the RNA was positioned using vaccinia MTase VP39 structures (PDB entry 1AV6) (26, 30, 44) . The mutagenesis study also allowed identifying residues that strongly reduce MTase activity with a weak effect on RNA recognition (D99, F149, F150, H41, and N43) . On the basis of their position in the structural model, we suggest that these residues might participate in SAM binding.
We then demonstrated that SAM/SAH balance plays an important role in nsp10-nsp16 interaction. The methyl donor SAM, strengthens the interaction between nsp10 and nsp16 at the physiological intracellular concentration (100 M [36] ) and, in turn, the RNA binding properties of nsp16 are enhanced. This suggests that SAM stabilizes or induces small conformational changes of the enzyme leading to an increase in both RNA affinity and methylation by nsp10/nsp16. This observation is also consistent with thermal shift assay indicating that the nsp10/nsp16 complex is stabilized in the presence of SAM (delta melting temperature [ΔTm] Ϸ 1°C). During RNA methylation, SAM is converted into SAH. The SAH will be next released by nsp16 stimulating the dissociation of the nsp10/nsp16 complex. In addition, the reaction product (cap-1 RNA) barely interacts with the nsp10/nsp16 complex and is released. Overall, these observations suggest that cap-0 RNA methylation is linked to the association and dissociation of the nsp10/nsp16 complex (Fig. 8) . These data also suggest that the SAM/SAH balance in infected cells is a key factor for cap RNA methylation. Since SAH hydrolase is a key enzyme for maintaining low levels of SAH in cells, inhibitors of cellular SAH hydrolases might have an antiviral effect on CoV replication. Interestingly, the SAH hydrolase inhibitor 3-deazaneplanocin A has previously been shown to inhibit several viruses (45) . It was recently demonstrated to limit Ebola virus replication and to lead to IFN-␣ production in virus-infected mice (46, 47) . The SAH hydrolase inhibitors may thus confer a selective antiviral activity that differ from one virus to another depending on their RNA methylation levels (48) . The inhibition may have the direct effect of an SAH concentration increase on the viral MTase or have indirect effects on cellular mRNA cap methylation, which may then be recognized as "non-self" and thus trigger an IFN response.
The viral 2=-O-MTase was highlighted as a potential antiviral target (38) . Indeed, such RNA methylation could be a marker of "self," thus avoiding detection of viral RNA by Mda5/RIG-I sensors (16, 18, 19) . In addition, one IFN-stimulated gene product, IFIT1, sequesters 2=O-unmethylated viral RNA and thereby blocks its translation, which results in inhibition of viral replication (49) . Thus, compounds blocking the viral 2=-O-MTase could limit viral replication in infected animals and elicit a strong antiviral response, favoring viral clearance. Here, we show that SAM analogues, such as SAH and sinefungin, limit 2=-O-MTase activity, with IC 50 s in the micromolar range (7.0 and 7.4 M, respectively) with no inhibition of RNA binding, as expected. Conversely, a N7-methylated cap analogue ( 7m GpppG) inhibits both 2=-O-MTase activity and RNA recognition, with an IC 50 of 45 M. This indicates that 7m GpppG acts as a competitive inhibitor that blocks cap-0 RNA recognition by the nsp10/nsp16 complex. This was confirmed by the absence of inhibition in the presence of unmethylated cap analogues. Altogether, these results might help in developing an efficient assay to screen compounds that inhibit the SAM-dependent MERS-CoV nsp10/nsp16 complex. The biochemical tools and the RNA binding assay allow the determination of whether inhibitors are competing directly with the RNA substrate. It remains to be tested whether Luria-Bertani and 2YT media containing 100 g/ml ampicillin and 17 g/ml chloramphenicol. Protein expression was induced by the addition of 0.5 mM IPTG (isopropyl-␤-D-thiogalactopyranoside). After overnight incubation at 17°C, cells expressing nsp10, nsp16, or a mixture of nsp10 and nsp16 (in equal volumes) were pelleted by centrifugation (13,000 ϫ g, 10 min) and frozen before resuspension in lysis buffer (50 mM HEPES [pH 7.5], 300 mM NaCl, 30 mM imidazole, 10% glycerol supplemented with 1 mM phenylmethylsulfonyl fluoride, 0.25 mg/ml lysozyme, 10 g/ml DNase I). After sonication and clarification (80,000 ϫ g, 4°C, 30 min), the supernatants were incubated with HisPur cobalt resin (Thermo Scientific) at 4°C with gentle shaking for 30 min. After washing in buffer W [50 mM HEPES (pH 7.5), 40 mM imidazole, 10% glycerol, and 1 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl)] containing 300 or 500 mM NaCl, bound proteins were eluted with buffer W supplemented with 250 mM imidazole. Recombinant nsp10 and nsp16 proteins were then concentrated by ultrafiltration devices with molecular mass cutoffs of 5 (Millipore) and 10 (Sartorius) kDa, respectively.
The nsp10/nsp16 complex was purified on a Superdex 200 column 16/60 (GE) equilibrated with buffer W containing 500 mM NaCl (GE ÄKTA purifier). After peak collection, fractions containing the nsp10/nsp16 complex were concentrated by ultrafiltration using 10-kDa Vivaspin 15 (Sartorius). All purified proteins were analyzed by SDS-PAGE, followed by Coomassie blue staining. Purified enzymes were stored at Ϫ20°C in 50% glycerol for enzymatic assays. (Fig. 2A) . The purified nsp10/nsp16 complex was used at 1 M. Reaction mixtures were incubated at 30°C and stopped at the indicated time points by diluting the reaction mixture with a 10-fold excess of 20 microM ice-cold SAH (AdoHcy, New England BioLabs). Samples were then transferred to DEAE filters (Perkin-Elmer) by using a Filtermat Harvester apparatus (Packard Instruments). Unincorporated 3 H-SAM was removed from the DEAE filters by several washes with 0.01 M ammonium formate (pH 8.0), H 2 O, and absolute ethanol. After drying, filters were incubated with BetaplateScint (Wallac) scintillation fluid before quantification of the 3 H methylation of the RNA substrates using a Wallac 1450 MicroBetaTriLux liquid scintillation counter (results were expressed as counts per minute [cpm]).
For the MTase inhibition assays, 0.5 M nsp10/nsp16 complex was mixed with 50 M each candidate inhibitor before addition of SAM (AdoMet; New England BioLabs) and 7m GpppGAUUUAA to start the reaction. The final dimethyl sulfoxide (DMSO) concentration in the reaction mixtures was lower than 5%, and control reaction mixtures contained a similar DMSO concentration. Reaction mixtures were incubated at 30°C for 30 min and then analyzed by filter binding assay, as described above.
The IC 50 s of SAH (AdoHcy), sinefungin, and cap analogues ( 7m GpppA and 7m GpppG) were determined with GraphPad Prism by using a log (inhibitor) versus a response variable slope equation.
Fluorescence polarization assays. (i) RNA labeling. For RNA labeling, 10 M RNA was labeled by ligation of 12.5 M pCp-cyanine 5 (pCp-cy5; Jena Bioscience) at the 3= extremity using 1 mM T4 RNA ligase-1 (New England BioLabs) in 50 mM Tris-HCl [pH 7.5], 10 mM MgCl 2 , 1 mM DTT, and 1 mM ATP at 16°C overnight, according to the manufacturer's instruction. T4 RNA ligase-1 was removed using Strata-Clean Resin (Agilent) and labeled RNA was collected after centrifugation in a Micro-Spin G-25 column (GE health care) to eliminate the free pCp-Cy5 dye.
(ii) Polarization assay. For the polarization assay, pCp-Cy5-labeled RNA was mixed with increasing concentrations of freshly purified nsp10/nsp16 complex, nsp10, or nsp16 in binding buffer (50 mM Tris-HCl [pH 8], 1 mM DTT) in a 384-well opaque microplate (Greiner Bio-One). Fluorescence polarization was measured using a microplate reader (PHERAstar) with a 590/675 fluorescence polarization optic module (i.e., 590-nm excitation and 675-nm emission wavelengths). The dissociation constants (K d ) were determined using nonlinear regression analysis: site-specific binding with Hill slope equation (GraphPad Prism). The competitive effect of cap analogues on 7m GpppGAUUUAA-cy5 binding by 20 M nsp10/ nsp16 complex were determined by using increasing concentrations of GpppG or 7m GpppG (New England BioLabs) in binding buffer. Data were plotted in GraphPad Prism 5.0 and a nonlinear sigmoidal dose-response curve fitted in order to determine the IC 50 values for RNA binding inhibition.
Interferometry for nsp10-nsp16 interaction. (i) nsp10 biotinylation. nsp10 was biotinylated (at room temperature for 30 min) using EZ-Link NHS-PEG4-biotin (Thermo Fisher) at a molar ratio of 1:1 in biotinylation buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 10% glycerol, 1 mM TCEP). Biotinylated nsp10 was separated from free biotin using NAP-5 columns equilibrated with biotinylation buffer.
(ii) Octet analysis. Assays were performed using streptavidin sensors preincubated in 50 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 1 mM TCEP, and 0.5 mg/ml bovine serum albumin (BSA). Biotinylated nsp10 (100 nM) was loaded on streptavidin-coated biosensors for 5,000 s to achieve 0.8-nm binding. Various nsp16 concentrations (0 to 7.8 M) were used for the association step (300 s) performed in 50 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 1 mM TCEP, and 0.5 mg/ml BSA. The dissociation step was followed for 500 s. Real-time nsp10-nsp16 interaction kinetics were recorded by using biolayer interferometry (Octet RED96). The K d , K on , and K off values were calculated using forteBio software after subtraction of the reference sensor from the sample traces. All curves were fitted using a 1:1 interaction model. The steady-state curve of nsp10-nsp16 interaction was traced using one site-specific binding with the Hill slope equation (GraphPad Prism).
Synthesis of RNA substrates. RNAs were chemically synthesized on a solid support using an ABI 394 synthesizer. After RNA elongation with 2=-O-pivaloyloxymethyl phosphoramidite monomers (Chem-genes, USA) (50), the 5=-hydroxyl group was phosphorylated, and the resulting H-phosphonate derivative was oxidized and activated into a phosphoroimidazolidate derivative to react with pyrophosphate (pppRNA) (51) or GDP (GpppRNA) (52) . After deprotection and release from the solid support, pppRNAs and GpppRNAs were purified by ion exchange high-pressure liquid chromatography (IEX-HPLC), and their purity (Ͼ95%) confirmed by MALDI-TOF spectrometry. N7 methylation of purified GpppRNAs was then performed enzymatically using an N7-hMTase (52) .
Mass spectrometry and IEX-HPLC analysis. Crude pppRNAs and GpppRNAs were analyzed and purified by IEX-HPLC on a Dionex Ultimate 3000 apparatus equipped with an UV detector at the wavelength of 260 nm and an anion-exchange DionexDNAPac PA200 column (4 by 250 mm for analysis or 9 by 250 mm for semipreparative purpose) with a flow rate of 1.5 ml/min for analysis or 5 ml/min for semipreparative purposes. The following eluents were used: buffer A (20% CH 3 CN in 25 mM Tris-HCl [pH 8]) and buffer B (20% CH 3 CN containing 200 mM NaClO 4 in 25 mM Tris-HCl [pH 8]). After purification, pure fractions containing the desired RNA were pooled in a 100-ml round-bottomed flask and concentrated to dryness under reduced pressure. The residues were desalted on a C 18 cartridge (Sep-Pak Classic).
MALDI-TOF mass spectra were recorded on a Voyager-DE (PerSeptive Biosystems, USA) or on an AXIMA Assurance spectrometer (Shimadzu Corp., Japan) equipped with an N 2 laser (337 nm) using 2,4,6-trihydroxyacetophenone as a saturated solution in a mixture of acetonitrile and 0.1 M ammonium citrate solution (1:1, vol/vol) for the matrix. The ionization mode was a linear negative ion mode. Analytical samples were mixed with the matrix in a 1:5 (vol/vol) ratio, crystallized on a 100-well stainless steel plate, and analyzed.
